NIH starts Phase II trial of Zika vaccine

NIH’s National Institute of Allergy and Infectious Diseases (NIAID) began the Phase II/IIb VRC 705 trial of its DNA plasmid Zika vaccine ZIKVwt (VRC-ZKADNA090-00-VP).

The trial's first part will determine an optimal dose of the vaccine in 90 healthy volunteers. The second, double-blind part will evaluate its efficacy in 2,400 volunteers. The NIAID expects to complete the trial by 2019...